Literature DB >> 11840283

Surface antigen expression in chronic lymphocytic leukemia: clustering analysis, interrelationships and effects of chromosomal abnormalities.

J Hulkkonen1, L Vilpo, M Hurme, J Vilpo.   

Abstract

Chronic lymphocytic leukemia (CLL) is a phenotypically distinguishable form of B-lymphoid leukemias. The regularity of surface membrane antigen expression patterns, their interrelationships as well as the effects of the three frequent chromosomal aberrations, ie 11q deletion, 13q deletion and trisomy 12, were investigated in 35 classic CLL cases by flow cytometry. The two-way cluster analysis of 31 individual antigens revealed three expression patterns: (1) most cells in most cases positive (CD5, CD19, CD20, CD23, CD27, CD40, CD45, CD45RA); (2) most cells in most cases negative (CD10, CD14, CD34, CD122, CD154, mIgG); and (3) a mixed pattern with a variable number of positive cases and a variable percentage of positive cells in individual cases (CD11c, CD21, CD22, CD25, CD38, CD45RO, CD79b, CD80, CD95, CD124, CD126, CD130, FMC7, mIgD, mIgkappa, mIglambda, mIgM). The expressions of several antigens were strongly interdependent, even when antigens belonged to entirely different gene families. Such antigen pairs were: CD11c/CD21; CD19/CD45; CD19/CD79b; CD22/CD45RA; CD23/Igkappa; CD25/mIgM; CD27/CD45; CD45/CD79b; CD45RA/Igkappa. In contrast, the expression of some antigens was mutually exclusive, the best examples being CD45RA/CD45RO, CD38/CD80 and CD45RA/CD80. Deletion of chromosome arm 11q attenuated expression of splicing variant CD45RA, but enhanced CD45RO expression. In contrast, cases of trisomy 12 were associated with enhanced CD45RA and attenuated CD45RO expression. Similarly, trisomy 12 was associated with enhanced CD27 and mIgkappa expression. The variable levels of signaling surface membrane antigens, their interactions and interference by genetic aberrations are likely to affect the clinical progression and drug response of CLL.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11840283     DOI: 10.1038/sj.leu.2402363

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  15 in total

1.  CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells.

Authors:  Rajendra N Damle; Sonal Temburni; Carlo Calissano; Sophia Yancopoulos; Taraneh Banapour; Cristina Sison; Steven L Allen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2007-08-07       Impact factor: 22.113

Review 2.  Investigational immunotherapeutics for B-cell malignancies.

Authors:  Alfonso Quintás-Cardama; William Wierda; Susan O'Brien
Journal:  J Clin Oncol       Date:  2010-01-04       Impact factor: 44.544

3.  The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.

Authors:  Mohammad Luqman; Sha Klabunde; Karen Lin; Georgios V Georgakis; Anu Cherukuri; Jocelyn Holash; Cheryl Goldbeck; Xiaomei Xu; Edward E Kadel; Sang Hoon Lee; Sharon Lea Aukerman; Bahija Jallal; Natasha Aziz; Wen-Kai Weng; William Wierda; Susan O'Brien; Anas Younes
Journal:  Blood       Date:  2008-05-22       Impact factor: 22.113

4.  Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

Authors:  John C Byrd; Thomas J Kipps; Ian W Flinn; Januaro Castro; Thomas S Lin; William Wierda; Nyla Heerema; James Woodworth; Steve Hughes; Shabnam Tangri; Sarah Harris; Dee Wynne; Arturo Molina; Bryan Leigh; Susan O'Brien
Journal:  Blood       Date:  2009-10-20       Impact factor: 22.113

Review 5.  Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells.

Authors:  Rajendra N Damle; Carlo Calissano; Nicholas Chiorazzi
Journal:  Best Pract Res Clin Haematol       Date:  2010-03       Impact factor: 3.020

Review 6.  Automated Analysis of Clinical Flow Cytometry Data: A Chronic Lymphocytic Leukemia Illustration.

Authors:  Richard H Scheuermann; Jack Bui; Huan-You Wang; Yu Qian
Journal:  Clin Lab Med       Date:  2017-12       Impact factor: 1.935

7.  Intensity of antigen expression reflects IGHV mutational status and Dohner-defined prognostic categories in chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis, and small lymphocytic lymphoma.

Authors:  Jayalakshmi Balakrishna; Neil Basumallik; Robert Matulonis; Drake Scott; Dalia Salem; Gregory Jasper; Adrian Wiestner; Maryalice Stetler-Stevenson; Gerald Marti; Clare Sun; Constance M Yuan
Journal:  Leuk Lymphoma       Date:  2021-03-18

Review 8.  Immunotherapy in Chronic Lymphocytic Leukaemia (CLL).

Authors:  Ciara L Freeman; John G Gribben
Journal:  Curr Hematol Malig Rep       Date:  2016-02       Impact factor: 3.952

Review 9.  Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia.

Authors:  Veronika Mancikova; Michal Smida
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

Review 10.  Does B cell receptor signaling in chronic lymphocytic leukaemia cells differ from that in other B cell types?

Authors:  Joseph R Slupsky
Journal:  Scientifica (Cairo)       Date:  2014-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.